BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 11590896)

  • 1. Clinical course of patients with IgA nephropathy between combined treatment of immunosuppressive agents and ACE inhibitor and ACE inhibitor alone.
    Hwang YC; Lee TW; Kim MJ; Yang MH; Ihm CG
    Korean J Intern Med; 2001 Jun; 16(2):105-9. PubMed ID: 11590896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ACEI/ATRA therapy decreases proteinuria by improving glomerular permselectivity in IgA nephritis.
    Woo KT; Lau YK; Wong KS; Chiang GS
    Kidney Int; 2000 Dec; 58(6):2485-91. PubMed ID: 11115082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of immunosuppressive therapy in IgA nephropathy presenting with isolated hematuria.
    Harmankaya O; Oztürk Y; Baştürk T; Obek A; Kiliçarslan I
    Int Urol Nephrol; 2002; 33(1):167-71. PubMed ID: 12090325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prednisolone and azathioprine in IgA nephropathy - a ten-year follow-up study.
    Goumenos DS; Davlouros P; El Nahas AM; Ahuja M; Shortland JR; Vlachojannis JG; Brown CB
    Nephron Clin Pract; 2003; 93(2):C58-68. PubMed ID: 12616032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment with low-dose angiotensin-converting enzyme inhibitor (ACEI) plus angiotensin II receptor blocker (ARB) in pediatric patients with IgA nephropathy.
    Yang Y; Ohta K; Shimizu M; Nakai A; Kasahara Y; Yachie A; Koizumi S
    Clin Nephrol; 2005 Jul; 64(1):35-40. PubMed ID: 16047643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy.
    Manno C; Torres DD; Rossini M; Pesce F; Schena FP
    Nephrol Dial Transplant; 2009 Dec; 24(12):3694-701. PubMed ID: 19628647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ACE gene polymorphism and renal responsiveness to ACE inhibitors in IgA nephropathy patients.
    Han SY; Kwon YJ; Jo SK; Shin JH; Cha DR; Cho WY; Pyo HJ; Kim HK
    Korean J Intern Med; 2000 Jan; 15(1):13-8. PubMed ID: 10714086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment and outcome of IgA nephropathy in children from one single center experience.
    Mao Y; Zhou W; Zhou Z; Zhang C; Shen J; Yin L
    BMC Pediatr; 2023 Jul; 23(1):377. PubMed ID: 37495962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fractional urinary excretion of IgG is the most powerful predictor of renoprotection by ACE inhibitors in IgA nephropathy.
    Bazzi C; Rizza V; Paparella M; Casellato D; Napodano P; Olivieri G; D'Amico G
    J Nephrol; 2009; 22(3):387-96. PubMed ID: 19557716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclophosphamide pulse therapy in advanced progressive IgA nephropathy.
    Rasche FM; Klotz CH; Czock D; Karges W; Muche R; Jehle PM; Mertz A; Keller F
    Nephron Clin Pract; 2003; 93(4):c131-6. PubMed ID: 12759581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Steroid and cyclophosphamide therapy for IgA nephropathy associated with crescenteric change: an effective treatment.
    McIntyre CW; Fluck RJ; Lambie SH
    Clin Nephrol; 2001 Sep; 56(3):193-8. PubMed ID: 11597033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of antiproteinuric effects of two different combination therapies in children with IgA nephropathy.
    Yagi K; Okada M; Yanagida H; Kuwajima H; Ikeda M; Sugimoto K; Takemura T
    Clin Exp Nephrol; 2003 Dec; 7(4):270-4. PubMed ID: 14712355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histologically advanced IgA nephropathy treated successfully with prednisolone and cyclophosphamide.
    Mitsuiki K; Harada A; Okura T; Higaki J
    Clin Exp Nephrol; 2007 Dec; 11(4):297-303. PubMed ID: 18085391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic effect of mycophenolate mofetil and angiotensin-converting enzyme inhibitor in patients with chronic allograft nephropathy.
    Moscoso-Solorzano GT; Mastroianni-Kirsztajn G; Ozaki KS; Franco MF; Pacheco-Silva A; Câmara NO
    Braz J Med Biol Res; 2009 May; 42(5):445-52. PubMed ID: 19377794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Immunosuppressive therapy in IgA glomerulonephritis with chronic renal failure: case study presentation and literature review].
    Pozzi C; Del Vecchio L; Locatelli F
    G Ital Nefrol; 2002; 19(5):523-8. PubMed ID: 12439840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of the effectiveness of cyclophosphamide, leflunomide, corticosteroids, or conservative management alone in patients with IgA nephropathy: a retrospective observational study.
    Chen S; Yin Q; Ren S; Zhong X; Wang W; Li G; Wang L
    Sci Rep; 2018 Sep; 8(1):13662. PubMed ID: 30209279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The effects of angiotensin-converting enzyme inhibitor on IgA nephropathy and the influencing factors].
    Shi X; Chen X; Liu S; Zhuang Y; Zhang Y
    Zhonghua Nei Ke Za Zhi; 2002 Jun; 41(6):399-403. PubMed ID: 12137603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective trial of combined therapy with heparin/warfarin and renin-angiotensin system inhibitors in progressive IgA nephropathy.
    Ishii T; Kawamura T; Tsuboi N; Ogura M; Utsunomiya Y; Hosoya T
    Contrib Nephrol; 2007; 157():114-9. PubMed ID: 17495447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual renin-angiotensin system blockade plus oral methylprednisone for the treatment of proteinuria in IgA nephropathy.
    Trimarchi H; Muryan A; Young P; Forrester M; Iotti A; Pereyra H; Lombi F; Seminario O; Alonso M; Iotti R
    Medicina (B Aires); 2007; 67(5):445-50. PubMed ID: 18051227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of cytotoxic therapy in progressive IgA nephropathy.
    Shin JH; Lee JE; Park JH; Lim S; Jang HR; Kwon GY; Huh W; Jung SH; Kim YG; Oh HY; Kim DJ
    Ann Med; 2016; 48(3):171-81. PubMed ID: 27031662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.